A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and colleagues around the world, has discovered that the genes we are born with—known as germline genetic variants—play a powerful, underappreciated role in how cancer develops and behaves.
Published in the April 14 online issue of Cell, the study, “Precision Proteogenomics Reveals Pan-Cancer Impact of Germline Variants,” is the first to detail how millions of inherited genetic differences influence the activity of thousands of proteins within tumors.
Drawing on data from more than 1,000 patients across 10 different cancer types, the research illustrates how a person’s unique genetic makeup can shape the biology of their cancer.